Novartis AG 2024 IR
The report highlights Novartis' first full year as a pure-play medicines company, delivering strong financial performance with double-digit growth in net sales and net profit. The company reached 296 million patients globally and advanced its pipeline with key approvals, including Fabhalta for IgA nephropathy and Kisqali for early breast cancer. On environmental matters, Novartis reduced its Scope 1 and 2 emissions by 20% compared to the previous year, putting it on track for its 2025 carbon neutrality target. Additionally, the company achieved gender balance in management, with women representing 48% of leadership roles.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2024
Type: IR
Pages: 75
Back to company
Novartis AG
Integrated Report
The report highlights Novartis' first full year as a pure-play medicines company, delivering strong financial performance with double-digit growth in net sales and net profit. The company reached 296 million patients globally and advanced its pipeline with key approvals, including Fabhalta for IgA nephropathy and Kisqali for early breast cancer. On environmental matters, Novartis reduced its Scope 1 and 2 emissions by 20% compared to the previous year, putting it on track for its 2025 carbon neutrality target. Additionally, the company achieved gender balance in management, with women representing 48% of leadership roles.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees